Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.

Nitulescu, Ioana I; Meyer, Sara C.; Wen, Qiang Jeremy; Crispino, John D; Lemieux, Madeleine E; Levine, Ross L; Pelish, Henry E; Shair, Matthew D (2017). Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. EBioMedicine, 26, pp. 112-125. Elsevier 10.1016/j.ebiom.2017.11.013

[img]
Preview
Text
1-s2.0-S2352396417304565-main.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (2MB) | Preview

Constitutive JAK-STAT signaling drives the proliferation of most myeloproliferative neoplasms (MPN) and a subset of acute myeloid leukemia (AML), but persistence emerges with chronic exposure to JAK inhibitors. MPN and post-MPN AML are dependent on tyrosine phosphorylation of STATs, but the role of serine STAT1 phosphorylation remains unclear. We previously demonstrated that Mediator kinase inhibitor cortistatin A (CA) reduced proliferation of JAK2-mutant AML in vitro and in vivo and also suppressed CDK8-dependent phosphorylation of STAT1 at serine 727. Here we report that phosphorylation of STAT1 S727 promotes the proliferation of AML cells with JAK-STAT pathway activation. Inhibition of serine phosphorylation by CA promotes growth arrest and differentiation, inhibits colony formation in MPN patient samples and reduces allele burden in MPN mouse models. These results reveal that STAT1 pS727 regulates growth and differentiation in JAK-STAT activated neoplasms and suggest that Mediator kinase inhibition represents a therapeutic strategy to regulate JAK-STAT signaling.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Meyer, Sara Christina

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2352-3964

Publisher:

Elsevier

Language:

English

Submitter:

Julia Elisa Garcia

Date Deposited:

21 Dec 2023 14:20

Last Modified:

21 Dec 2023 14:29

Publisher DOI:

10.1016/j.ebiom.2017.11.013

PubMed ID:

29239838

Uncontrolled Keywords:

CDK8 Cortistatin A Kinase inhibitor Leukemia MPN Ruxolitinib STAT1 Super-enhancer

BORIS DOI:

10.48350/190298

URI:

https://boris.unibe.ch/id/eprint/190298

Actions (login required)

Edit item Edit item
Provide Feedback